Zensights Q2 2026 Market Update
Zensights Q2 2026 Market Update The latest insights on M&A activity in life sciences commercial vendors As part of our quarterly pharmaceutical industry review, we are pleased to share an update on merger and acquisition activity to help our clients...
Zensights Q1 2026 Market Update
Zensights Q1 2026 Market Update The latest insights on M&A activity in life sciences commercial vendors As part of our quarterly pharmaceutical industry review, we are pleased to share an update on merger and acquisition activity to help our clients understand...
Presidential Executive Order Banning DTC Advertising
Presidential Executive Order Banning DTC Advertising What If the Saber Rattling Came to Fruition? By ZENSIGHTS December 2025 Executive Summary For nearly four decades, direct-to-consumer (DTC) pharmaceutical advertising has been a defining feature of the United...
Zensights Q4 2025 Market Update – Perspectives
Zensights Q4 2025 Market Update The latest insights on M&A activity in life sciences commercial vendors As part of our quarterly pharmaceutical industry review, we're pleased to share an update on merger and acquisition activity to help our clients understand the...
Alternative Funding Programs: Enabling Access or Eroding Value?
Alternative Funding Programs: Enabling Access or Eroding Value? The Pharma Dilemma By ZENSIGHTS Subject Matter Expert Eric Brandon December 2025 Executive Summary The rising cost of specialty medications has become one of the most pressing challenges in modern...
Zensights Q3 2025 Market Update
Zensights Q3 2025 Market Update The latest insights on M&A activity in life sciences commercial vendors As part of our quarterly pharmaceutical industry review, we're pleased to share an update on merger and acquisition activity to help our clients understand the...
Pharmaceutical Industry Response to Most-Favored-Nation Pricing Directive:
Pharmaceutical Industry Response to Most-Favored-Nation Pricing Directive: A Comprehensive Analysis By ZENSIGHTS October 2025 Executive Summary In July 2025, President Trump sent letters to 17 major pharmaceutical manufacturers demanding they implement...
Zensights Q2 2025 Market Update
Zensights Q2 2025 Market Update The latest insights on M&A activity in life sciences commercial vendors As part of our LINX bio-pharma vendor review, Zensights is pleased to share an update on merger activity to help our clients understand the market activity...
Accelerating Market Success: Strategic Innovation Through NextGen Medical Affairs
Accelerating Market Success: Strategic Innovation ThroughNextGen Medical Affairs By ZENSIGHTS July 2025 Executive Summary In today’s complex pharmaceutical landscape, Medical Affairs plays a vital role in connecting scientific innovation with real-world adoption....









